Daiichi Sankyo Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Daiichi Sankyo Company Limited with three other
companies in this sector in Japan:
Mitsubishi Tanabe Pharma Corp
sales of 423.98 billion Japanese Yen [US$3.78 billion]
of which 74%
was Domestic Ethical Drug),
Astellas Pharma Incorporated
(1.31 trillion Japanese Yen [US$11.69 billion]
of which 58%
was Other), and
Eisai Company Limited
(539.10 billion Japanese Yen [US$4.80 billion]
of which 54%
was Pharmaceutical Business -Japan).
Daiichi Sankyo Company Limited reported sales of ¥955.12 billion (US$8.51 billion)
March of 2017.
decrease of 3.2%
versus 2016, when the company's sales were ¥986.45 billion.
The sales level in 2017 was fairly close to the level five years ago: in 2012, Daiichi Sankyo Company Limited had sales
of ¥938.68 billion.
Contributing to the drop in overall sales was the 4.8% decline
in Prescription Drugs, from ¥930.32 billion to ¥885.57 billion.
There were also decreases in sales in
Other (down 3.2% to ¥2.67 billion)
However, these declines were partially offset by the increase in sales of
Healthcare Products (up 25.3% to ¥66.88 billion)